The patient journey has changed dramatically over the past decade. What was once a relatively simple path, visit the doctor, receive a diagnosis, pick up a prescription, and start treatment, has evolved into a much more complex experience for patients. Today, patients must navigate a series of steps that often include genetic testing, specialist referrals, […]
Read more
Every year, millions of prescriptions are written that patients never start. Some patients never pick up their medication. Others start therapy but stop within weeks. For healthcare systems, pharmaceutical companies, and providers alike, this represents one of the most expensive and preventable failures in modern medicine. In the United States alone, roughly one in four […]
Read more
Today we released a press announcement that addresses something pharma leaders already feel in their forecasts, but rarely quantify directly: Patient dropout is quietly draining $250 billion from the U.S. pharmaceutical market every year. You can read the full announcement here:https://www.prnewswire.com/news-releases/pharma-is-losing-250-billion-to-patient-dropout-heres-how-to-stop-it-302696178.html Not because therapies do not work. Not because innovation has slowed. But because patients […]
Read more
What Happens When You Shut Down a Call Center Without a Plan? Pharmaceutical patient services teams are under immense pressure. Costs are rising. Staffing is unstable. Call center turnover is high. And leadership teams are being asked a difficult question: “Can we afford to keep this call center running?” But there is a far more […]
Read more
Pharmaceutical brands are delivering extraordinary science to market. Yet an increasing percentage of prescribed patients never initiate therapy. Not because the product does not work.Not because physicians are not prescribing it. But because the moment education leaves the physician’s hands, initiation risk skyrockets. The hidden gap between prescription and start From a brand perspective, the […]
Read more
Listen to Episode 1: Pharma’s Direct to Patient Pivot: What to Expect in 2026 here. The pharmaceutical industry is moving faster than patients can keep up. Therapies are becoming more specialized. Disease education is more complex. Access models are shifting Direct to Patient. At the same time, physician time is shrinking and patients are being […]
Read more
Enterprise pharma is moving decisively toward direct-to-patient models. This is not a marketing trend or a side project. It is a structural response to access friction, pricing pressure, and the consumerization of healthcare. Patients are behaving more like consumers, distribution models are shifting, and manufacturers are being pulled closer to the patient experience whether they […]
Read more
Specialty therapies are increasingly effective, targeted, and personalized. At the same time, they are becoming more complex for patients to manage. Treatment success in specialty care often depends not only on clinical efficacy but on a patient’s ability to understand, remember, and consistently act on treatment requirements over time. These cognitive demands are rarely measured, […]
Read more
The recent ChatGPT Health announcement has sparked significant discussion across healthcare. With more than 40 million people asking ChatGPT a healthcare question every day, the reality is clear. Patients have already been using AI to fill a gap that has existed for years. That gap is not a lack of clinical expertise. It is a […]
Read more
Healthcare organizations invest significant time and resources into educating patients about their treatments. Clinicians explain diagnoses, outline care plans, distribute written materials, and direct patients to digital resources. Yet across specialty care, a persistent gap exists between how education is delivered and how patients actually learn. This gap has meaningful implications. Specialty therapies are often […]
Read more